Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction.

Holmberg C, Bandos H, Fagerlin A, Bevers TB, Battaglia TA, Wickerham DL, McCaskill-Stevens WJ.

Cancer Prev Res (Phila). 2017 Nov;10(11):625-634. doi: 10.1158/1940-6207.CAPR-17-0076. Epub 2017 Oct 4.

PMID:
28978566
2.

Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.

Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL 3rd, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx162.

PMID:
28954297
3.

Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.

Rivera DR, Ganz PA, Weyrich MS, Bandos H, Melnikow J.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx140. Review.

PMID:
28954296
4.

Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study.

Blakeslee SB, McCaskill-Stevens W, Parker PA, Gunn CM, Bandos H, Bevers TB, Battaglia TA, Fagerlin A, Müller-Nordhorn J, Holmberg C.

Patient Educ Couns. 2017 Dec;100(12):2346-2354. doi: 10.1016/j.pec.2017.06.033. Epub 2017 Jun 27.

PMID:
28734560
5.

Exploring Explanatory Models of Risk in Breast Cancer Risk Counseling Discussions: NSABP/NRG Oncology Decision-Making Project 1.

Gunn CM, Bokhour B, Parker VA, Parker PA, Blakeslee S, Bandos H, Holmberg C.

Cancer Nurs. 2017 Jun 28. doi: 10.1097/NCC.0000000000000517. [Epub ahead of print]

PMID:
28661894
6.

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.

Gavin PG, Song N, Kim SR, Lipchik C, Johnson NL, Bandos H, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE Jr, Jeong JH, Costantino JP, Wolmark N, Paik S, Pogue-Geile KL.

JAMA Oncol. 2017 Mar 1;3(3):335-341. doi: 10.1001/jamaoncol.2016.4884.

7.

Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy.

Jatoi I, Bandos H, Jeong JH, Anderson WF, Romond EH, Mamounas EP, Wolmark N.

J Natl Cancer Inst. 2015 Oct 30;108(1). pii: djv304. doi: 10.1093/jnci/djv304. Print 2016 Jan.

8.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S.

J Natl Cancer Inst. 2013 Dec 4;105(23):1782-8. doi: 10.1093/jnci/djt321. Epub 2013 Nov 21.

9.

Cognitive factors associated with adherence to oral antiestrogen therapy: results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study.

Klepin HD, Geiger AM, Bandos H, Costantino JP, Rapp SR, Sink KM, Lawrence JA, Atkinson HH, Espeland MA.

Cancer Prev Res (Phila). 2014 Jan;7(1):161-8. doi: 10.1158/1940-6207.CAPR-13-0165. Epub 2013 Nov 19.

10.

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.

Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N.

Lancet Oncol. 2013 Nov;14(12):1183-92. doi: 10.1016/S1470-2045(13)70411-X. Epub 2013 Oct 4.

PMID:
24095300
11.

Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial.

Danhauer SC, Legault C, Bandos H, Kidwell K, Costantino J, Vaughan L, Avis NE, Rapp S, Coker LH, Naughton M, Naylor C, Terracciano A, Shumaker S.

Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2013;20(5):532-52. doi: 10.1080/13825585.2012.747671. Epub 2012 Dec 14.

12.

Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).

Cecchini RS, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Bandos H, Weissfeld JL, Wolmark N.

Cancer Prev Res (Phila). 2012 Nov;5(11):1321-9. doi: 10.1158/1940-6207.CAPR-12-0273. Epub 2012 Oct 11.

13.

Regression on quantile residual life.

Jung SH, Jeong JH, Bandos H.

Biometrics. 2009 Dec;65(4):1203-12. doi: 10.1111/j.1541-0420.2009.01196.x.

14.

Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21.

Fisher ER, Costantino JP, Leon ME, Bandos H, Palekar AS, Fisher B, Wolmark N.

Cancer. 2007 Nov 1;110(9):1929-36.

Supplemental Content

Loading ...
Support Center